Of common genetic alterations seen in CRC, KRAS variants were of particular interest because of their frequency (approximately 50% incidence in metastatic CRC) and because they carry treatment implications; their presence was associated with resistance to treatment with anti–epidermal growth factor receptor medications, such as panitumumab and cetuximab.9,10 Whether a KRAS variation was independently associated with prognostic mortality profiles had been a complex and controversial topic that evolved over decades with increased testing availability. This evidence concerns the gene KRAS and colorectal carcinoma.